Heptares Therapeutics

Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets. The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.
Type
Subsidiary
HQ
Welwyn Garden City, GB
Founded
2007
Heptares Therapeutics was founded in 2007 and is headquartered in Welwyn Garden City, GB

Heptares Therapeutics Office Locations

Heptares Therapeutics has an office in Welwyn Garden City
Welwyn Garden City, GB (HQ)
Broadwater Rd

Heptares Therapeutics Financials and Metrics

Heptares Therapeutics Summary

Founding Date

2007

Total Funding

$26 m

Investors

In total, Heptares Therapeutics had raised $26 m

Heptares Therapeutics Financials

Heptares Therapeutics's revenue was reported to be £17 m in FY, 2016 which is a 231% increase from the previous period.
GBPFY, 2012FY, 2013FY, 2014FY, 2016

Revenue

5.6 m9.7 m5.2 m17 m

Operating expense total

12.7 m15.5 m16.1 m35 m

EBITDA

(5.2 m)(10.4 m)(17.4 m)

EBITDA margin, %

(53%)(201%)(102%)
GBPFY, 2012FY, 2013FY, 2014FY, 2016

Net Income

(5.3 m)(4.2 m)(8.2 m)(8.7 m)

Cash From Operating Activities

(7.1 m)(4.7 m)(11.8 m)

Cash From Financing Activities

8.5 m6.5 m9 m

Net Change in Cash

2.5 m3.2 m(1.4 m)
    Show all financial metrics

    Heptares Therapeutics's Web-traffic and Trends

    Heptares Therapeutics Online and Social Media Presence

    Heptares Therapeutics Company Life and Culture

    You may also be interested in